• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

第5至8外显子内外的p53基因突变:乳腺癌与其他癌症中的模式有所不同。

p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.

作者信息

Hartmann A, Blaszyk H, McGovern R M, Schroeder J J, Cunningham J, De Vries E M, Kovach J S, Sommer S S

机构信息

Department of Oncology, Mayo Clinic and Foundation, Rochester, Minnesota 55905.

出版信息

Oncogene. 1995 Feb 16;10(4):681-8.

PMID:7862445
Abstract

Most studies of mutations in the p53 tumor suppressor gene in tumors have examined only exons 5-8. Our laboratory previously found 64 mutations in exons 5-8 of the p53 gene in 194 primary breast cancers. Herein, we report 18 additional mutations found outside of exons 5-8. Mutations are present in exons 4, 9 and 10, and flanking splice junctions, but not in the promotor region or in exons 1, 2, 3 and 11. No missense mutations are found outside of exons 5-8. Instead, there is a predominance of frameshift mutations with lesser numbers of nonsense and splice site mutations. In contrast, the majority of mutations in exons 5-8 in this sample are missense changes and all of these are at amino acids that are identical in the 11 known p53 sequences that represent about 1.6 billion years of evolutionary divergence. The difference in mutational pattern between these two regions of the p53 gene is due to a lack of missense mutations and inframe microdeletions outside of exons 5-8. A review of our database of p53 mutations (De Vries et al., in preparation) shows that the patterns of mutation inside and outside of exons 5-8 differ in other types of cancers as well. The paucity of missense mutations in exons 2-4 and 9-11 in breast and other cancers (even at amino acids identical throughout p53 gene evolution) suggest that at least some missense mutations result in a phenotype other than malignant transformation. These data also illustrate the importance of examining identical exons when comparing the pattern of p53 gene mutations in different populations.

摘要

大多数关于肿瘤中p53肿瘤抑制基因的突变研究仅检测了外显子5至8。我们实验室先前在194例原发性乳腺癌中发现了p53基因外显子5至8中的64个突变。在此,我们报告在5至8号外显子之外又发现的18个突变。这些突变存在于外显子4、9和10以及侧翼剪接位点,但不存在于启动子区域或外显子1、2、3和11中。在5至8号外显子之外未发现错义突变。相反,移码突变占主导,无义突变和剪接位点突变数量较少。相比之下,该样本中外显子5至8中的大多数突变是错义变化,并且所有这些错义变化都发生在11个已知p53序列中相同的氨基酸位置,这些序列代表了约16亿年的进化分歧。p53基因这两个区域之间突变模式的差异是由于5至8号外显子之外缺乏错义突变和框内微缺失。对我们的p53突变数据库(De Vries等人,正在准备中)的回顾表明,5至8号外显子内外的突变模式在其他类型的癌症中也有所不同。乳腺癌和其他癌症中外显子2至4以及9至11中错义突变的缺乏(即使在p53基因进化过程中相同的氨基酸位置)表明,至少一些错义突变导致的表型不是恶性转化。这些数据还说明了在比较不同人群中p53基因突变模式时检查相同外显子的重要性。

相似文献

1
p53 gene mutations inside and outside of exons 5-8: the patterns differ in breast and other cancers.第5至8外显子内外的p53基因突变:乳腺癌与其他癌症中的模式有所不同。
Oncogene. 1995 Feb 16;10(4):681-8.
2
p53 gene mutations in breast cancers in midwestern US women: null as well as missense-type mutations are associated with poor prognosis.
Oncogene. 1994 Oct;9(10):2869-75.
3
Splice-site mutation of the p53 gene in a family with hereditary breast-ovarian cancer.一个遗传性乳腺癌-卵巢癌家族中p53基因的剪接位点突变。
Oncogene. 1994 Jan;9(1):97-102.
4
High frequency of deletion mutations in p53 gene from squamous cell lung cancer patients in Taiwan.台湾肺癌鳞状细胞癌患者p53基因缺失突变的高频率
Cancer Res. 1998 Jan 15;58(2):328-33.
5
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.对2至11号外显子进行DNA序列分析和免疫组织化学染色,以检测人类恶性肿瘤中所有已知的p53改变。
Oncogene. 1996 Nov 7;13(9):1971-81.
6
Molecular epidemiology of breast cancers in northern and southern Japan: the frequency, clustering, and patterns of p53 gene mutations differ among these two low-risk populations.
Oncogene. 1996 Nov 21;13(10):2159-66.
7
TP53 mutational pattern in Spanish and Polish non-small cell lung cancer patients: null mutations are associated with poor prognosis.西班牙和波兰非小细胞肺癌患者的TP53突变模式:无效突变与预后不良相关。
Oncogene. 1997 Dec 11;15(24):2951-8. doi: 10.1038/sj.onc.1201475.
8
p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.免疫组织化学染色未检测到的p53无效突变预示早期非小细胞肺癌预后不良。
Cancer Res. 1999 Nov 1;59(21):5572-7.
9
Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer.p53基因不同结构和功能区域的突变在乳腺癌中的预后意义。
Clin Cancer Res. 2000 Feb;6(2):443-51.
10
Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.原发性头颈癌与相应的上消化道第二原发性癌中p53基因的不一致突变。
Cancer Res. 1993 Apr 1;53(7):1676-83.

引用本文的文献

1
Atox1-cyclin D1 loop activity is critical for survival of tumor cells with inactivated TP53.Atox1-cyclin D1 循环活性对于 TP53 失活的肿瘤细胞的存活至关重要。
Biosci Rep. 2024 Jun 26;44(6). doi: 10.1042/BSR20240389.
2
The carcinogenic capacity of arsenic in normal epithelial breast cells and double-positive breast cancer cells.砷在正常乳腺上皮细胞和双阳性乳腺癌细胞中的致癌能力。
Med Pharm Rep. 2024 Apr;97(2):184-195. doi: 10.15386/mpr-2682. Epub 2024 Apr 25.
3
The p53 Protein Family in the Response of Tumor Cells to Ionizing Radiation: Problem Development.
肿瘤细胞对电离辐射反应中的p53蛋白家族:问题进展
Acta Naturae. 2021 Jul-Sep;13(3):65-76. doi: 10.32607/actanaturae.11247.
4
TP53 Mutations and Outcomes in Breast Cancer: Reading beyond the Headlines.TP53 基因突变与乳腺癌结局:超越头条的解读。
Trends Cancer. 2020 Feb;6(2):98-110. doi: 10.1016/j.trecan.2020.01.007. Epub 2020 Feb 5.
5
p53, cathepsin D, Bcl-2 are joint prognostic indicators of breast cancer metastatic spreading.p53、组织蛋白酶D、Bcl-2是乳腺癌转移扩散的联合预后指标。
BMC Cancer. 2016 Aug 18;16:649. doi: 10.1186/s12885-016-2713-3.
6
Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.人乳腺癌中TP53错义突变免疫组化检测的合理手动及自动评分阈值
Appl Immunohistochem Mol Morphol. 2016 Jul;24(6):398-404. doi: 10.1097/PAI.0000000000000207.
7
Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.TP53 突变相关 microRNAs 的表达预测头颈部鳞状细胞癌患者的临床结局。
Ann Oncol. 2013 Dec;24(12):3082-8. doi: 10.1093/annonc/mdt380. Epub 2013 Oct 9.
8
TP53 genetic alterations in Arab breast cancer patients: Novel mutations, pattern and distribution.阿拉伯乳腺癌患者中的TP53基因改变:新突变、模式及分布
Oncol Lett. 2011 Mar;2(2):363-369. doi: 10.3892/ol.2011.236. Epub 2011 Jan 18.
9
Relationship between expression of apoptosis-related proteins and the efficacy of postoperative chemotherapy in patients with T3 gastric cancer.凋亡相关蛋白的表达与 T3 期胃癌患者术后化疗疗效的关系。
Surg Today. 2012 Feb;42(3):225-32. doi: 10.1007/s00595-011-0062-z. Epub 2011 Dec 6.
10
Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome.通过 AQUA 对西南肿瘤协作组主导的乳腺癌试验 S9313 的多重评估显示,HER2 高水平和低水平均与不良预后相关。
Am J Pathol. 2010 Apr;176(4):1639-47. doi: 10.2353/ajpath.2010.090711. Epub 2010 Feb 11.